Gregory Oakes Net Worth

Gregory Oakes biography

Gregory Oakes serves as Independent Director of the Company. Mr. Oakes brings over 25 years of pharmaceutical industry and leadership experience and currently serves as Corporate Vice President, Global Integration Lead for Otezla® (apremilast) at Amgen, Inc. where he is responsible for the integration and continued success for sustained growth of the brand with $2 billion in assets. Prior to Amgen from 2017 - 2019, Mr. Oakes served as Corporate Vice President and U.S. General Manager at Celgene Corp., a global biopharmaceutical company which develops and commercializes medicines for cancer and inflammatory disorders. Mr. Oakes also served as the Global Commercial Integration Lead at Celgene where he helped steer the $74 billion acquisition by Bristol-Myers Squibb and the $13.4 billion divestiture of Otezla®. From 2010 to 2017, Mr. Oakes held several positions at Novartis AG, the most recent as Head of Sandoz Biopharmaceuticals, North America. He began his career at Schering-Plough (Merck) where he held executive roles in both the U.S. and Europe. Mr. Oakes holds a bachelor's degree in Marketing and Business Administration from Edinboro University and a M.B.A. from Clemson University. He currently sits on the Board of BioNJ and previously served on various Executive Committees at Celgene, Novartis, and Schering- Plough (Merck).

How old is Gregory Oakes?

Gregory Oakes is 52, he's been the Independent Director of AzurRx BioPharma Inc since 2020. There are 7 older and 1 younger executives at AzurRx BioPharma Inc. The oldest executive at AzurRx BioPharma Inc is Vern Schramm, 78, who is the Independent Director.

What's Gregory Oakes's mailing address?

Gregory's mailing address filed with the SEC is C/O AZURRX BIOPHARMA, INC., 1615 SOUTH CONGRESS AVENUE, SUITE 103, DELRAY BEACH, FL, 33445.

Insiders trading at AzurRx BioPharma Inc

Over the last 8 years, insiders at AzurRx BioPharma Inc have traded over $510,400 worth of AzurRx BioPharma Inc stock and bought 335,700 units worth $727,436 . The most active insiders traders include Charles J Casamento, Edmund Burke Jr. Ross, and Partners Llcbalk Matthew Pe.... On average, AzurRx BioPharma Inc executives and independent directors trade stock every 82 days with the average trade being worth of $262,052. The most recent stock trade was executed by Johan M. Spoor on 28 December 2018, trading 38,583 units of AZRX stock currently worth $50,158.

What does AzurRx BioPharma Inc do?

AzurRx BioPharma Inc executives and stock owners

AzurRx BioPharma Inc executives and other stock owners filed with the SEC include:

• James R. Sapirstein R.Ph., M.B.A.,
  CEO, Pres & Non-Independent Director
• James Pennington,
  Chief Medical Officer
• James Sapirstein,
  President, Chief Executive Officer, Director
• Alastair Riddell,
  Independent Director
• Edward Borkowski,
  Independent Chairman of the Board
• Vern Schramm,
  Independent Director
• Charles Casamento,
  Independent Director
• Gregory Oakes,
  Independent Director
• Daniel Schneiderman,
  Chief Financial Officer
• Martin Krusin M.B.A.,
  Sr. VP of Corp. Devel.
• Johan M. Spoor,
  
• Partners Llcbalk Matthew Pe...,
  
• Edmund Burke Jr. Ross,
  
• Maged Shenouda,
  CHIEF FINANCIAL OFFICER
• Daniel Dupret,
  CHIEF SCIENTIFIC OFFICER
• Mary Theresa Coelho,